Overview

Dopaminergic Loss and Pain in Parkinson's Disease

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
0
Participant gender:
All
Summary
About 46% of patients suffering from Parkinson's disease present pain disorders. Parkinson disease is characterized by loss of dopaminergic neurons. The aim of this study is to assess the relationship between the loss of dopaminergic neurons and the existence of pain in Parkinson's disease. Using single photon emission computerized tomography (SPECT) imaging (123I FP-CIT, which binds dopamine transporter) and the determination of subjective pain threshold, the investigators will establish correlations between dopaminergic degeneration and pain perception.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital, Toulouse
Treatments:
2beta-carbomethoxy-3beta-(4-iodophenyl)tropane
Dopamine
RTI 55
Criteria
Inclusion Criteria:

- Patients with clinically established Parkinson's disease according to the UKPDSBB (UK
Parkinson's Disease Society Brain Bank) (Gibb et Less, 1998; Hugues et al, 1992).

- Male or Female patients, aged from 30 to 70 years.

- Patients must benefit from the French Social security system.

- Patients must give a written informed consent.

- Female fertile patients must use an efficient method of contraception.

If patients suffer from chronic pain, pain must be related to Parkinson's disease.

Exclusion Criteria:

- Patients with a syndrome other than the idiopathic Parkinson's disease.

- Patients suffering from important trembling during the OFF periods or abnormal
involuntary movements (dyskinesia) during the ON periods, not allowing the imagery
exam to be performed.

- Patients suffering from another disease causing chronic pain.

- Patients suffering from cancer.

- Patients with cognitive dysfunction.

- Patients not able to complete the scales.

- Pregnant, breastfeeding or fertile female patients not using an efficient method of
contraception.

- Patients not willing to participle in the trial.